Details

Autor(en) / Beteiligte

• See, Isaac
• Lale, Allison
• Marquez, Paige
• Streiff, Michael B
• Wheeler, Allison P
• Tepper, Naomi K
• Woo, Emily Jane
• Broder, Karen R
• Edwards, Kathryn M
• Gallego, Ruth
• Geller, Andrew I
• Jackson, Kelly A
• Sharma, Shashi
• Talaat, Kawsar R
• Walter, Emmanuel B
• Akpan, Imo J
• Ortel, Thomas L
• Urrutia, Victor C
• Walker, Shannon C
• Yui, Jennifer C
• Shimabukuro, Tom T
• Mba-Jonas, Adamma
• Su, John R
• Shay, David K

Titel

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021

Ist Teil von

• Annals of internal medicine, 2022-04, Vol.175 (4), p.513

Ort / Verlag

United States

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. It presents similarly to spontaneous heparin-induced thrombocytopenia. Twelve cases of cerebral venous sinus thrombosis after vaccination with the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson) have previously been described. To describe surveillance data and reporting rates of all reported TTS cases after COVID-19 vaccination in the United States. Case series. United States. Case patients receiving a COVID-19 vaccine from 14 December 2020 through 31 August 2021 with thrombocytopenia and thrombosis (excluding isolated ischemic stroke or myocardial infarction) reported to the Vaccine Adverse Event Reporting System. If thrombosis was only in an extremity vein or pulmonary embolism, a positive enzyme-linked immunosorbent assay for antiplatelet factor 4 antibodies or functional heparin-induced thrombocytopenia platelet test result was required. Reporting rates (cases per million vaccine doses) and descriptive epidemiology. A total of 57 TTS cases were confirmed after vaccination with Ad26.COV2.S (  = 54) or a messenger RNA (mRNA)-based COVID-19 vaccine (  = 3). Reporting rates for TTS were 3.83 per million vaccine doses (Ad26.COV2.S) and 0.00855 per million vaccine doses (mRNA-based COVID-19 vaccines). The median age of patients with TTS after Ad26.COV2.S vaccination was 44.5 years (range, 18 to 70 years), and 69% of patients were women. Of the TTS cases after mRNA-based COVID-19 vaccination, 2 occurred in men older than 50 years and 1 in a woman aged 50 to 59 years. All cases after Ad26.COV2.S vaccination involved hospitalization, including 36 (67%) with intensive care unit admission. Outcomes of hospitalizations after Ad26.COV2.S vaccination included death (15%), discharge to postacute care (17%), and discharge home (68%). Underreporting and incomplete case follow-up. Thrombosis with thrombocytopenia syndrome is a rare but serious adverse event associated with Ad26.COV2.S vaccination. The different demographic characteristics of the 3 cases reported after mRNA-based COVID-19 vaccines and the much lower reporting rate suggest that these cases represent a background rate. Centers for Disease Control and Prevention.